World Desk, Amar Ujala, London
Updated Thu, 10 Dec 2020 11:01 AM IST
Corona vaccine (file photo)
– Photo: Amar Ujala (File Photo)
Hear the news
Pfizer has begun vaccination by completing a trial of the Corona vaccine in the UK. She is now exploring possibilities in India. She has applied to the regulatory body for emergency approval in India.
The US company requires a temperature of minus 70 degrees to protect its vaccine, while cold storage facilities with such low temperatures are not available in India. To overcome this problem, the company is preparing a new version of the vaccine.
It is not necessary to keep minus 70 degrees
Pfizer CEO Albert Borla said, ‘We are working on a new formulation. Which will not need to be stored at minus 70 degrees. It can be stored under normal refrigeration. ‘ Meanwhile, the Canadian health regulator has also approved the use of Pfizer vaccines.
More data sought from Serum-Bharat Biotech
Pfizer, Serum Institute of India and Bharat Biotech’s application to approve emergency use of their vaccine was discussed by the expert committee of CDSCO on Wednesday. Pfizer has asked for more time for the presentation. At the same time, Serum and Bharat Biotech have been asked to provide some more data. The committee has asked Serum to present the updated data for the second and third phase trials. Data from Phase II and Phase III trials have also been sought from Bharat Biotech, which is making indigenous covicin.